ImmunOs Therapeutics Appoints Michael A. Curran, PhD, as Chairman of its Scientific Advisory Board
Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 – ImmunOs Therapeutics AG , a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Michael A. Curran, PhD , has been appointed Chairman of the Company´s Scientific Advisory Board.